Answers are grounded in this paper and cite their sources.
Demonstrates improved drug delivery using mixed micelles in cancer therapy, suggesting better safety compared to commercial vehicles.
To address the limitations of commercial vehicles for paclitaxel (PTX) delivery, this study investigated mixed micelles as a novel delivery system for this drug. By incorporating PCL5000-PEG5000 into DSPE-PEG2000 at 99.5:0.5 and 99:1 molar ratios, we aimed to enhance drug loading and biocompatibility. The resulting systems were characterized using a range of physicochemical and biological characterization. The system achieved a low critical micelle concentration (CMC) of 1.9 × 10–5 mol/L, ensuring stability upon dilution. Optimized formulations (99.5:0.5 and 99:1 molar ratios) exhibited a small hydrodynamic diameter (∼11 nm) and near-neutral zeta potential. Small-range X-ray scattering (SAXS) analysis confirmed a spheroidal core–shell structure, where the addition of 0.5% PCL5000-PEG5000 increased drug loading capacity to 3.1 ± 0.05% w/w. Thermal analysis confirmed the successful integration of copolymers and their thermal stability. Notably, the cytotoxicity of this formulation was comparable to that of commercial formulations, while exhibiting negligible hemolysis (<2%), indicating a substantially improved safety profile compared with Cremophor-based vehicles. These findings highlight the potential of these mixed micelles as a biocompatible, high-capacity delivery platform for intravenous cancer chemotherapy.
No takes yet. Share an insight, caveat, or question.
Maia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: